MASH cirrhosis treatment, fibrosis reversal, and population screening were cited by experts as hepatology's biggest gaps.
Mazen Noureddin, MD, MHSc
Advertisement
Mazen Noureddin, MD, MHSc, is a professor of medicine and a transplant hepatologist at Houston Methodist Hospital.
Articles by Mazen Noureddin, MD, MHSc
Phase 2 data for DD01 and pemvidutide show liver-directed MASH benefits beyond weight loss, with strong tolerability heading into phase 3.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers
2
Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies
3
Ebola Cases Top 1700 as Unpaid Health Workers Strike
4
Upcoming 2026 FDA Decisions Could Expand Treatment Options Across Oncology and Hepatitis B
5